NECLIFE

Nectar Lifesciences Share Price

 

Stock Hit Lower Circuit

 

Start SIP in NECLIFE

Start SIP

Performance

  • Low
  • ₹20
  • High
  • ₹20
  • 52 Week Low
  • ₹13
  • 52 Week High
  • ₹41
  • Open Price₹20
  • Previous Close₹21
  • Volume55,037

Investment Returns

  • Over 1 Month + 33.93%
  • Over 3 Month + 39.32%
  • Over 6 Month -10.95%
  • Over 1 Year -49.14%

Smart Investing Starts Here Start SIP with Nectar Lifesciences for Steady Growth!

Invest Now

Nectar Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -1.2
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 451
  • P/B Ratio
  • 0.6
  • Average True Range
  • 0.84
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.55
  • RSI
  • 54.8
  • MFI
  • 71.27

Nectar Lifesciences Financials

Nectar Lifesciences Technicals

EMA & SMA

Current Price
₹20.09
-1.05 (-4.97%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹20.07
  • 50 Day
  • ₹18.03
  • 100 Day
  • ₹17.73
  • 200 Day
  • ₹20.15

Resistance and Support

20.09 Pivot Speed
  • R3 20.09
  • R2 20.09
  • R1 20.09
  • S1 20.09
  • S2 20.09
  • S3 20.09

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nectar Lifesciences manufactures and supplies pharmaceuticals, active pharmaceutical ingredients (APIs), and herbal products. With state-of-the-art facilities in India, the company serves global markets, focusing on healthcare, wellness, and life-saving medications for various therapeutic segments.

Nectar Lifesciences has an operating revenue of Rs. 1,171.34 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of -10% needs improvement, ROE of -11% is poor and needs improvement. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 26% and 10% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 6 which is a POOR score indicating inconsistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nectar Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results & Others To consider other business matters.
2025-07-23 Others Inter alia amongst other items, the mode of rewarding of shareholders as contemplated in the explanatory statement to item no. 3 of Notice of 2025-26/01st EGM or matters related thereto.
2025-07-07 Audited Results
2025-01-31 Quarterly Results & Others To consider other business matters.

Nectar Lifesciences F&O

Nectar Lifesciences Shareholding Pattern

44.91%
0%
0.62%
44.7%
9.77%

About Nectar Lifesciences

  • NSE Symbol
  • NECLIFE
  • BSE Symbol
  • 532649
  • Chairman & Managing Director
  • Mr. Sanjiv Goyal
  • ISIN
  • INE023H01027

Similar Stocks to Nectar Lifesciences

Nectar Lifesciences FAQs

Nectar Lifesciences share price is ₹20 As on 27 December, 2025 | 12:42

The Market Cap of Nectar Lifesciences is ₹450.5 Cr As on 27 December, 2025 | 12:42

The P/E ratio of Nectar Lifesciences is -1.2 As on 27 December, 2025 | 12:42

The PB ratio of Nectar Lifesciences is 0.6 As on 27 December, 2025 | 12:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23